LRRK2 kinase inhibition achieved greater than 90% target engagement in peripheral tissue and roughly 30% reduction in CSF phospho-Rab10, yet 648 patients with early-stage Parkinson’s disease showed no measurable slowing of motor decline over up to 144 weeks. That gap — near-complete target hit, zero clinical signal — is the central problem LUMA leaves behind, and it implicates the target itself, not the drug.

The primary endpoint was time to confirmed worsening on a combined MDS-UPDRS Parts II and III score, a composite that captures both patient-reported and clinician-assessed motor function. It is a meaningful, functional bar, and BIIB122 cleared none of it. Neither did any secondary endpoint. The biomarker story makes the null result harder to explain away: drug levels in blood and CSF were sustained, kinase inhibition was real, and yet the downstream biology did not translate into neurological benefit. One interpretation is that LRRK2 activity in idiopathic Parkinson’s — where LRRK2 mutations account for only 1–2% of sporadic cases — is not a meaningful disease driver in the broader population. Another is that 48–144 weeks is simply insufficient to detect neuroprotective benefit on motor endpoints in early disease. LUMA cannot distinguish between those possibilities.

What separates this failure from a clean program termination is the BEACON study, which Denali is running independently in confirmed pathogenic LRRK2 variant carriers — the population where hyperactive LRRK2 kinase is a genetic certainty, not a hypothesis. BEACON is designed around pharmacokinetics and lysosomal biomarkers rather than clinical endpoints, which is the appropriate scope for a Phase 2a in a genetically stratified cohort. If phospho-Rab10 reductions in that population correlate with lysosomal pathway rescue, the mechanistic case for LRRK2 inhibition survives in a narrow but scientifically coherent indication. If they do not, the target is effectively closed.

The full LUMA dataset — presumably including subgroup analyses in the variant-carrier enrollees who were included — has not been published, only announced. When that data is presented at conference, the carrier subgroup response rate will determine whether BEACON is a scientifically justified pivot or a sunk-cost rationale for keeping a program alive.

Source link: https://www.globenewswire.com/news-release/2026/05/21/3299824/0/en/Biogen-and-Denali-Therapeutics-Provide-Update-on-Phase-2b-LUMA-Study-of-BIIB122-DNL151-in-Early-Stage-Parkinson-s-Disease.html

BIIB122: the facts in one place

  • Also written: liradasertib, BIIB122/DNL151
  • Sponsor: Biogen and Denali Therapeutics
  • Mechanism: LRRK2 kinase inhibitor, selective, CNS-penetrant small molecule
  • Indication studied: early-stage Parkinson’s disease, including idiopathic and LRRK2-associated forms
  • Phase: Phase 2b (LUMA); Phase 2a (BEACON)
  • Enrollment: 648 (LUMA); approximately 50 (BEACON)
  • Primary endpoint: LUMA: time to confirmed worsening in modified MDS-UPDRS Part II and III combined score; BEACON: adverse events
  • Headline result: LUMA did not meet its primary or secondary endpoints; exploratory biomarkers showed greater than 90% target engagement in peripheral tissue and approximately 30% reduction in CSF phospho-Rab10
  • Registry identifier: NCT05348785, NCT06602193
  • Current status: Development discontinued for idiopathic Parkinson’s disease as of May 21, 2026; Denali continues BEACON study in LRRK2-associated Parkinson’s disease
  • Phase 2b LUMA study initiated: May 31, 2022
  • First participant dosed in Phase 2a BEACON study: December 5, 2024
  • Discontinuation of development for idiopathic Parkinson’s disease announced: May 21, 2026
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.